Easterly Investment Partners’s Integra LifeSciences IART Stock Holding History

Easterly Investment Partners’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-61,454	Closed	-$1.12M	–	208
2024 Q3	$1.12M	Sell	61,454 -245,700	-80%	-$5.7M	0.09%	153
2024 Q2	$8.95M	Buy	307,154 +7,095	+2%	+$210K	0.79%	49
2024 Q1	$10.6M	Buy	300,059 +4,957	+2%	+$198K	0.81%	46
2023 Q4	$12.9M	Buy	295,102 +240,446	+440%	+$9.46M	1.37%	22
2023 Q3	$2.09M	Buy	54,656 +29,802	+120%	+$1.25M	0.23%	95
2023 Q2	$1.02M	Sell	24,854 -24,869	-50%	-$1.2M	0.09%	145
2023 Q1	$2.85M	Buy	49,723 +7,148	+17%	+$403K	0.25%	95
2022 Q4	$2.39M	Buy	+42,575	New	+$2.17M	0.21%	97

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Easterly Investment Partners's IART Position: Q4 2024 in Review

Easterly Investment Partners sold out of Integra LifeSciences (IART) in Q4 2024, closing a stake of 61,454 shares — an estimated $1.12M sold.

Easterly Investment Partners first reported a position in IART in Q4 2022 and held it in 8 quarters. The position peaked at $12.9M in Q4 2023. 223 funds tracked by Wall St. Rank hold IART as of Q4 2024.

Easterly Investment Partners reported no remaining Integra LifeSciences position as of Q4 2024 after selling out during the quarter.
Easterly Investment Partners sold 61,454 Integra LifeSciences shares in Q4 2024, an estimated $1.12M.
Easterly Investment Partners first reported a position in Integra LifeSciences in Q4 2022 and held it in 8 quarters.
Easterly Investment Partners's Integra LifeSciences position peaked at $12.9M in Q4 2023.
223 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2024.

Based on Easterly Investment Partners's 13F filing for Q4 2024, filed 12 Feb 2025.